Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
OSTX Stock Forecast 2025-2026
$1.92
Current Price
$67.61M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to OSTX Price Targets
+941.7%
To High Target of $20.00
+316.7%
To Median Target of $8.00
+212.5%
To Low Target of $6.00
OSTX Price Momentum
+7.3%
1 Week Change
+5.5%
1 Month Change
+2.1%
1 Year Change
-55.1%
Year-to-Date Change
-72.6%
From 52W High of $7.00
+71.4%
From 52W Low of $1.12
📊 TOP ANALYST CALLS
Did OSTX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if OS Therapies is one of their latest high-conviction picks.
Latest OSTX Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, OSTX has a bullish consensus with a median price target of $8.00 (ranging from $6.00 to $20.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $1.92, the median forecast implies a 316.7% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason Kolbert at D. Boral Capital, projecting a 941.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
OSTX Analyst Ratings
4
Buy
0
Hold
0
Sell
OSTX Price Target Range
Low
$6.00
Average
$8.00
High
$20.00
Current: $1.92
Latest OSTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for OSTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 21, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Nov 18, 2025 | Lake Street | Chad Messer | Buy | Maintains | $17.00 |
| Nov 17, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $20.00 |
| Oct 10, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $20.00 |
| Sep 30, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $20.00 |
| Sep 12, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $20.00 |
| Sep 2, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $20.00 |
| Aug 27, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $20.00 |
| Aug 20, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $20.00 |
| Aug 7, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $20.00 |
| Jul 14, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $20.00 |
| Jul 3, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $20.00 |
| Jun 30, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $20.00 |
| Jun 24, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $20.00 |
| Jun 10, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $20.00 |
| Jun 9, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $20.00 |
| May 15, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $20.00 |
| Apr 22, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $20.00 |
| Apr 7, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $20.00 |
| Apr 2, 2025 | Lake Street | Chad Messer | Buy | Initiates | $19.00 |
Os Therapies Inc. (OSTX) Competitors
The following stocks are similar to OS Therapies based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
OSTX
OS Therapies
mkt cap
63.03M
Os Therapies Inc. (OSTX) Financial Data
Os Therapies Inc. has a market capitalization of $67.61M with a P/E ratio of -2.2x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -914.0%.
Valuation Metrics
Market Cap
$67.61M
Enterprise Value
$60.82M
P/E Ratio
-2.2x
PEG Ratio
-0.1x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+2.8%
Current Ratio
0.6x
Debt/Equity
0.0x
ROE
-914.0%
ROA
-225.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Os Therapies Inc. (OSTX) Business Model
About Os Therapies Inc.
What They Do
Develops innovative cancer treatments and therapies.
Business Model
The company focuses on research and commercialization of cancer therapies, particularly in the immunotherapy sector. It generates revenue by conducting clinical trials and developing products that enhance cancer treatment outcomes, ultimately improving patient quality of life.
Additional Information
Os Therapies Inc. is contributing to advancements in personalized medicine within the biotechnology and pharmaceutical industries, addressing significant challenges in cancer treatment and striving to make impactful contributions to both patients and the scientific community.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
4
CEO
Mr. Paul A. Romness M.P.H.
Country
United States
IPO Year
2024
Website
ostherapies.comOs Therapies Inc. (OSTX) Latest News & Analysis
Latest News
OS Therapies Receives Non-Proprietary Name 'daznelimgene lisbac' for OST-HER2 from World Health Organization
11 days ago
Quick Summary
OS Therapies Inc. (NYSE American: OSTX) announced WHO's approval of 'daznelimgene lisbac' as the non-proprietary name for its HER2-targeted cancer immunotherapy, OST-HER2, aimed at treating osteosarcoma.
Why It Matters
The WHO's approval of 'daznelimgene lisbac' enhances OS Therapies' credibility and market presence, potentially boosting investor confidence and stock value in the oncology sector.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
OS Therapies plans to spin off its subsidiary OS Animal Health into a standalone public company. The veterinary oncology market is projected to grow significantly from $1.58B in 2024 to $4.77B in 2034.
Why It Matters
OS Therapies' spin-off of OS Animal Health could unlock value in the growing veterinary oncology market, attracting investors seeking exposure to innovative cancer treatments for pets.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
OS Therapies Inc. (NYSE: OSTX) has made significant progress in clinical, regulatory, and commercial areas in Q3 2025, advancing towards delivering OST-HER2 for pulmonary metastatic osteosarcoma.
Why It Matters
OS Therapies' progress in clinical and regulatory milestones could enhance its market position and investor confidence, potentially leading to increased stock value as it approaches product launch.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
OS Therapies Inc. has scheduled a Type C Meeting with the FDA for December 11, 2025, regarding its OST-HER2 trial. BLA and MAA filings are expected in January 2025, with potential PRV eligibility by September 2026.
Why It Matters
The upcoming FDA meetings and regulatory milestones for OST-HER2 indicate potential market entry and financial implications, affecting investor sentiment and stock performance for OS Therapies.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
OS Therapies Inc. (NYSE American: OSTX) reported additional survival data from its Phase 2b trial of immunotherapy candidate OST-HER2 for recurrent pulmonary metastatic osteosarcoma.
Why It Matters
Positive survival data from OS Therapies' clinical trial enhances its credibility and potential market value, indicating progress in cancer treatment and attracting investor interest.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
OS Therapies Inc. will hold a final FDA Type C Meeting on December 11, 2025, to align on clinical efficacy data for the OST-HER2 BLA, following positive Phase 2b trial results for osteosarcoma.
Why It Matters
The FDA's Type C Meeting signals progress for OS Therapies' OST-HER2, potentially leading to accelerated approval. Positive outcomes could boost stock value and investor confidence significantly.
Source: Newsfile Corp
Market Sentiment:
Neutral
Frequently Asked Questions About OSTX Stock
What is Os Therapies Inc.'s (OSTX) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Os Therapies Inc. (OSTX) has a median price target of $8.00. The highest price target is $20.00 and the lowest is $6.00.
Is OSTX stock a good investment in 2026?
According to current analyst ratings, OSTX has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.92. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for OSTX stock?
Wall Street analysts predict OSTX stock could reach $8.00 in the next 12 months. This represents a 316.7% increase from the current price of $1.92. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Os Therapies Inc.'s business model?
The company focuses on research and commercialization of cancer therapies, particularly in the immunotherapy sector. It generates revenue by conducting clinical trials and developing products that enhance cancer treatment outcomes, ultimately improving patient quality of life.
What is the highest forecasted price for OSTX Os Therapies Inc.?
The highest price target for OSTX is $20.00 from Jason Kolbert at D. Boral Capital, which represents a 941.7% increase from the current price of $1.92.
What is the lowest forecasted price for OSTX Os Therapies Inc.?
The lowest price target for OSTX is $6.00 from at , which represents a 212.5% increase from the current price of $1.92.
What is the overall OSTX consensus from analysts for Os Therapies Inc.?
The overall analyst consensus for OSTX is bullish. Out of 4 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $8.00.
How accurate are OSTX stock price projections?
Stock price projections, including those for Os Therapies Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 6, 2025 11:43 AM UTC